SOLIGENIX, INC. (SNGX) Form 424B3 — Aug 7, 2026
Soligenix filed Prospectus Supplement No. 2 registering 5,330,560 shares of common stock underlying previously issued common warrants, and the supplement incorporates its Form 10-Q for the quarter ended June 30, 2026. The embedded quarterly report discloses substantial doubt about the company's ability to continue as a going concern. Cash was $9.8 million against a $4.8 million six-month net loss with management projecting runway into the second quarter of 2028, but shares outstanding more than doubled from 10.1 million to 21.6 million after ATM sales of 11.5 million shares at a weighted average $0.54, leaving only about $2.4 million of remaining ATM capacity as of July 31, 2026.
Key figures
- Eps
- -0.12 (Q2 2026 basic and diluted); -0.37 (six months 2026)
- Revenue
- 0
- Total Assets
- 10499470
- Cash Position
- 9811141
- Shares Outstanding
- 21765479
- Cash runway
- into the second quarter of 2028
- Working capital
- 6499947
- Accumulated deficit
- 249863451
- Atm termination date
- December 15, 2026 (latest)
- Hybryte wind down charges
- ~$70,000
- Warrant shares registered
- 5330560
- Atm weighted average price
- 0.54
- Shares issued atm six months
- 11538661
- Atm gross proceeds six months
- 6037818
- Nasdaq bid price cure deadline
- December 7, 2026
- Shares outstanding dec 31 2025
- 10086130
- Warrants outstanding june 30 2026
- 6798141
- Cash used in operations six months
- 4064414
- Atm remaining capacity july 31 2026
- ~$2.4 million
- Atm total sold through june 30 2026
- 6234000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.